Products
Nadifloxacin is commercially available as a cream (Nadixa). The drug is not registered in many countries. It has been approved in Japan since 1993 and in Germany since 2000.
Structure and properties
Nadifloxacin (C19H21FN2O4, Mr = 360.4 g/mol) is a 3rd generation fluoroquinolone. The figure shows the more active -nadifloxacin; the cream contains the racemate -nadifloxacin.
Effects
Nadifloxacin (ATC D10AF) is bactericidal against a broad spectrum of bacteria, including . Its effects are based on inhibition of DNA gyrase. Its use as an acne agent is not without controversy because of the potential for cross-resistance to other quinolones, such as levofloxacin.
Indications
For external use in mild to moderate manifestations of inflammatory forms of acne vulgaris. In Japan, the drug has also been approved since 1998 for the treatment of bacterial infections such as folliculitis.
Dosage
According to the SmPC. The drug is applied thinly twice daily. The skin should be dried beforehand and the cream should not be brought into contact with the eyes and lips. The duration of treatment is up to 8 weeks.
Contraindications
Nadifloxacin is contraindicated in cases of hypersensitivity. For complete precautions, see the drug label.
Interactions
Other concomitantly applied acne medications may increase the skin-irritating effect. Because of low absorption, systemic interactions are considered unlikely.
Adverse effects
Possible adverse effects include skin reactions such as itching, papules, dry skin, contact dermatitis, skin irritation, warm sensation, and flushing.
